Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia

Business Wire September 29, 2021

Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 28, 2021

Syros Announces Appointment of Conley Chee as Chief Commercial Officer

Business Wire September 27, 2021

Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer

Business Wire September 20, 2021

Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021

Business Wire September 13, 2021

Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors

Business Wire September 10, 2021

Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Business Wire September 9, 2021

Syros to Present at Upcoming Investor Conferences in September

Business Wire September 7, 2021

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire August 5, 2021

Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer

Business Wire August 5, 2021

Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Business Wire July 29, 2021

Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference

Business Wire June 9, 2021

Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio

Business Wire May 19, 2021

Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire May 6, 2021

Syros to Report First Quarter 2021 Financial Results on Thursday May 6, 2021

Business Wire April 29, 2021

Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire March 4, 2021

Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021

Business Wire February 25, 2021

Syros to Participate in Upcoming Investor Conferences in March

Business Wire February 22, 2021

Syros Announces Pricing of $75.6 Million Public Offering of Common Stock

Business Wire January 19, 2021

Syros Announces Proposed Offering of Common Stock

Business Wire January 19, 2021